drugset / Trial / NCT02867267

The Efficacy and Safety of Ta1 for Sepsis

NCT02867267 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether thymalfasin is safe and effective in patients who have sepsis

Timeline

Start
2016-09-06
Primary completion
2021-01-22
Completion
2021-03-23

Outcome

Missed primary endpoint

paper hazard ratio 0.99, 95% confidence interval 0.77 to 1.27; P=0.93 with log-rank test PMID 39814420 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Thymosin alpha 1 Peptide 1.6 mg Subcutaneous